# Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer

> **NCT00287885** · PHASE1 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 18 (actual)

## Conditions studied

- Cervical Cancer
- Endometrial Cancer
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer
- Sarcoma
- Vaginal Cancer
- Vulvar Cancer

## Interventions

- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00287885
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00287885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00287885, "Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00287885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*